Literature DB >> 19430303

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.

Aslam H Anis1, Bohdan Nosyk, Huiying Sun, Daphne P Guh, Nick Bansback, Xin Li, Paul G Barnett, Vilija Joyce, Kathleen M Swanson, Tassos C Kyriakides, Mark Holodniy, D William Cameron, Sheldon T Brown.   

Abstract

OBJECTIVE: To investigate the relative magnitude and duration of impact of AIDS-defining events (ADEs) and non-AIDS serious adverse events (SAEs) on health-related quality of life (HRQoL) among patients with advanced HIV/AIDS.
METHODS: We use data from OPTIMA (OPTions In Management with Antiretrovirals), a multinational, randomized, open, control, clinical management trial of treatment strategies for patients with multidrug-resistant HIV and advanced immune disease. Longitudinal models were used to determine the effects of ADEs and SAEs on HRQoL across periods before, during, and after event onset. The Medical Outcomes Study HIV Health Survey (MOS-HIV) physical and mental health summary scores (MOS-PHS and MOS-MHS), EQ-5D, and the Health Utilities Index Mark 3 HRQoL measures were all assessed at regular follow-up intervals during the trial.
RESULTS: ADEs occurred much less frequently than SAEs (n = 147 vs. n = 821) in the study sample population of 368 patients, during median follow-up of 3.96 years. Although both ADEs and SAEs had significant negative impacts on HRQoL, SAEs had at least as large an impact upon HRQoL as ADEs when both were included in a multivariate linear regression model, controlling for other covariates. However, the effect of ADEs on HRQoL was more persistent, with larger magnitude of effect across all instruments in time intervals further from the onset of the event.
CONCLUSIONS: Non-AIDS SAEs occurring in patients with late-stage HIV/AIDS seem to have at least as important an immediate impact on patient HRQoL as ADEs; however, the impact of ADEs seems to be more persistent. Our findings call for a greater emphasis on the detection and active prevention of non-AIDS SAEs in patients with late-stage HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430303     DOI: 10.1097/QAI.0b013e3181a4f00d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Authors:  Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

2.  Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Authors:  Ahmed M Bayoumi; Paul G Barnett; Vilija R Joyce; Susan C Griffin; Huiying Sun; Nick J Bansback; Mark Holodniy; Gillian Sanders; Sheldon T Brown; Tassos C Kyriakides; Brian Angus; D William Cameron; Aslam H Anis; Mark Sculpher; Douglas K Owens
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

3.  The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS.

Authors:  Bohdan Nosyk; Huiying Sun; Nick Bansback; Daphne P Guh; Xin Li; Paul Barnett; Ahmed Bayoumi; Susan Griffin; Vilija Joyce; Mark Holodniy; Doug K Owens; Aslam H Anis
Journal:  Qual Life Res       Date:  2009-06-27       Impact factor: 4.147

4.  Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women.

Authors:  Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin
Journal:  J Womens Health (Larchmt)       Date:  2015-03-09       Impact factor: 2.681

5.  Predictors of health-related quality of life among military HIV-infected individuals.

Authors:  Leonard Emuren; Seth Welles; Grace Macalino; Alison A Evans; Marcia Polansky; Anuradha Ganesan; Rhonda E Colombo; Brian K Agan
Journal:  Qual Life Res       Date:  2020-02-20       Impact factor: 4.147

6.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

7.  Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity.

Authors:  John R Keltner; Florin Vaida; Ronald J Ellis; Tobias Moeller-Bertram; Chelsea Fitzsimmons; Nichole A Duarte; Jessica Robinson-Papp; Robert H Dworkin; David B Clifford; Justin C McArthur; David M Simpson; Ann C Collier; Christina M Marra; J Hampton Atkinson; Igor Grant
Journal:  Psychosomatics       Date:  2012 Jul-Aug       Impact factor: 2.386

Review 8.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Initiation of antiretroviral therapy in youth with HIV: a U.S.-based provider survey.

Authors:  Christina Gagliardo; Meghan Murray; Lisa Saiman; Natalie Neu
Journal:  AIDS Patient Care STDS       Date:  2013-08-12       Impact factor: 5.078

10.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.